Optinose plans to raise funds through an initial public offering of 2.25 million shares of its common stock.

The underwriters will receive a 30-day option to buy an additional 675,000 shares.

Based in the US, Optinose is a pharmaceutical company focused on the development of innovative products for patients with ear, nose and throat (ENT) allergies.

The funds are intended to be used towards the commercialisation and further development of its XHANCE nasal spray indicated for the treatment of nasal polyps. The funds will also be used for working capital and other general corporate purposes.

Kitov Pharma has signed an agreement to raise $8.15m through a private placement of 3.26 million American Depositary Shares (ADS) priced at $2.50 per ADS.

The warrants will be exercisable at a price of $2.8 per ADS and have a term of 5.5 years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in Israel, Kitov is a biopharmaceutical company focused on end-to-end drug development.

Clovis Oncology and Immunomedics have collaborated to investigate the combination of the former’s poly polymerase inhibitor Rubraca with the latter’s lead product candidate sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) and metastatic urothelial cancer (mUC).

“Kitov Pharma has signed an agreement to raise $8.15m through a private placement of 3.26 million American Depositary Shares (ADS) priced at $2.50 per ADS.”

Based in the US, Clovis is a manufacturer of anti-cancer agents, while Immunomedics, also based in the US, is a biopharmaceutical company that provides novel immuno-therapeutics for the treatment of cancer and other serious diseases.

The collaboration enables the two companies to develop treatments for advanced breast and bladder cancers.

Bayer plans to raise €6bn ($7bn) through a rights offering of shares of its common stock.

Bayer simultaneously plans to raise €20bn ($23.31bn) through the issuance of bonds in a private placement.

The company plans to use the funds to support the proposed acquisition of Monsanto, an American agrochemical and agricultural biotechnology corporation.

Based in Germany, Bayer is a life science, chemical and pharmaceutical company.

Merrill Lynch, Pierce, Fenner & Smith and Credit Suisse Group were appointed as underwriters to Bayer for the offering.

Upsher-Smith Laboratories has signed a marketing and distribution agreement with an undisclosed pharmaceutical company for six ophthalmic and otic ANDA products.

Upsher-Smith will register the six products with the US Food and Drug Administration (FDA) and market them under its own brand in the US, post approval. The undisclosed pharmaceutical company will develop and produce the products solely for Upsher-Smith.

Based in the US, Upsher-Smith is a provider of high-quality pharmaceutical products.

The partnership enables Upsher-Smith to significantly expand its product pipeline.